8
total announcements
LINCOLN.NS · 15 min delayed
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited has informed the Exchange about dispatch of physical communication to shareholders who have not registered their email address. The company is also informing shareholders about the 32nd Annual General Meeting (AGM) and the Annual Report for the Financial Year 2025-26.
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited has informed the Exchange regarding Notice of 32nd Annual General Meeting to be held on September 30, 2026, to consider and adopt audited financial statements, declare dividend, and re-appoint directors.
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Sep-2026.
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding the 32nd Annual General Meeting of the Company to be held on Wednesday, September 30, 2026.
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited has informed the Exchange about the publication of un-audited financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of ₹3,623.45 lakhs and earnings per share of ₹18.09.
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on stock exchanges.
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.